Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jul 21, 2021 in Benign prostatic hyperplasia | 0 comments

In a nutshell

This study characterized the safety and effectiveness of greenlight photo-selective vaporization of the prostate (GL-PVP) in the treatment of benign prostatic hyperplasia (BPH). The data showed that under real-world conditions, GL-PVP provides a safe, effective, and durable BPH treatment option.

Some background

Lower urinary tract symptoms (LUTS) commonly occur in men with BPH. The standard treatment is a surgery called transurethral resection of the prostate (TURP). However, bleeding is common with TURP. Minimally invasive techniques such as GL-PVP are alternatives to TURP.

GL-PVP involves the use of a laser to vaporize excessive tissue in enlarged prostates. Compared to TURP, GL-PVP results in minimal bleeding. There is a need to determine the current, global state of GL-PVP by data collection from international centers through the Global Greenlight Group (GGG) database.

Methods & findings

This study analyzed data from 3627 patients with LUTS secondary to BPH. All patients underwent GL-PVP using the XPS-180 W system. Data were evaluated up to 60 months.

The average prostate-specific antigen (PSA; a protein made by the prostate gland) level was 3.1 ng/mL. On average, there was a 43.9% PSA reduction at 3 months and a 46.4 % reduction at 60 months, after the procedure. The average time of the procedure was 34 minutes. In 60.1% of patients, the catheter was removed one day after the procedure. 

Significant improvements in urinary symptoms and quality of life were seen at all timepoints during follow-up.

Most side effects were mild. 1.7% of patients experienced moderate and severe complications. 13.2% of patients had emergency room visits due to bloody urine. 10.5% of patients had urine leakage and 22.5% had urinary symptoms in the first month. After 6 months, 0.7% had urine leakage and 2.8% had urinary symptoms. 

The bottom line

The study showed that GL-PVP is a safe and effective treatment alternative for LUTS secondary to BPH.

The fine print

The study design did not allow certain types of data to be collected and longer follow-ups are needed.

Published By :

World Journal of Urology

Date :

Apr 10, 2021

Original Title :

Global Greenlight Group: largest international Greenlight experience for benign prostatic hyperplasia to assess efficacy and safety.

click here to get personalized updates